by
geography

New full data from a 52-week, Pfizer-sponsored study demonstrated no significant difference in six-month and one-year quit rates between a nicotine replacement therapy patch and Pfizer's Chantix. Although these results are disappointing for Pfizer, they open up the market to developmental vaccine treatments which are able to demonstrate greater safety and efficacy than available options.

Published By Datamonitor

Promising Phase III rheumatoid arthritis data for Pfizer's oral tasocitinib are set to emerge at this year's American College of Rheumatology meeting. As a first-in-class drug with the potential to address the unmet need for oral small molecules to treat rheumatoid arthritis, Datamonitor believes that it will have a distinct advantage. However, reasonable pricing will be crucial to its success.

Published By Datamonitor

Recently, Pfizer and AstraZeneca announced that they have signed a deal giving Pfizer marketing rights for the OTC version of the gastroesophageal reflux disease drug Nexium. Along with the cash-generating potential, the deal also strengthens Pfizer's consumer healthcare division, which can act synergistically with the company's innovative pharma business, especially in the emerging markets.

Published By Datamonitor

Pfizer has announced that a Phase III trial of Sutent in advanced pancreatic neuroendocrine tumors has reached its primary endpoint of improved progression-free survival. Given the niche, underserved nature of the advanced pancreatic neuroendocrine market, seeking a line extension in this indication may be a successful strategy for the company.

Published By Datamonitor

Phase II clinical trials of tanezumab in osteoarthritis, chronic low back pain and interstitial cystitis have demonstrated the drug's analgesic efficacy across these three chronic pain settings. Despite safety concerns and a high price point, Datamonitor expects tanezumab to enjoy a significant first-in-class advantage in a potentially lucrative novel area of pain therapy.

Published By Datamonitor

Published By Datamonitor

The last few years have seen renewed interest in the vaccines market, overcoming the prevailing view that vaccines are a low-margin business with high barriers to entry. The flu vaccines market has been at the forefront of this trend, partially fuelled by fear of an impending pandemic. This trend is set to continue, although flu vaccine revenues will depend on ambitious coverage targets being met.

Published By Datamonitor

The current outbreak of influenza A (H1N1) is testing pandemic preparedness strategies across the globe. While widely implemented strategies seem to have prepared the world better than ever before, important gaps regarding the logistics of drug and vaccine distribution remain.

Published By Datamonitor

Published By Datamonitor

Servier and Osteologix have entered into an agreement for the development and commercialization of Osteologix's novel dual acting bone agent for the treatment of osteoporosis, NBS101. While this partnership bodes well for the outlook of the drug in Europe, a medium or large US partner would unlock the treatment's true commercial potential.